Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Net Cash Flow (2021 - 2025)

Coeptis Therapeutics Holdings has reported Net Cash Flow over the past 5 years, most recently at $765815.0 for Q4 2025.

  • Quarterly results put Net Cash Flow at $765815.0 for Q4 2025, up 226.67% from a year ago — trailing twelve months through Dec 2025 was $5.1 million (up 649.15% YoY), and the annual figure for FY2025 was $5.1 million, up 649.15%.
  • Net Cash Flow for Q4 2025 was $765815.0 at Coeptis Therapeutics Holdings, down from $2.9 million in the prior quarter.
  • Over the last five years, Net Cash Flow for COEPW hit a ceiling of $5.0 million in Q3 2022 and a floor of -$4.2 million in Q4 2021.
  • Median Net Cash Flow over the past 5 years was -$91026.0 (2021), compared with a mean of -$49734.8.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 8442.3% in 2022 and later crashed 1149.16% in 2024.
  • Coeptis Therapeutics Holdings' Net Cash Flow stood at -$4.2 million in 2021, then rose by 14.09% to -$3.6 million in 2022, then skyrocketed by 101.61% to $57624.0 in 2023, then crashed by 1149.16% to -$604567.0 in 2024, then surged by 226.67% to $765815.0 in 2025.
  • The last three reported values for Net Cash Flow were $765815.0 (Q4 2025), $2.9 million (Q3 2025), and -$2.3 million (Q2 2025) per Business Quant data.